Evidence map›Paper›PMID 36652685›Full record

ArticleBlood advances2023

Genomics of PDGFR-rearranged hypereosinophilic syndrome.

Esther Rheinbay, Meifang Qi, Juliette M Bouyssou, Andrew J Oler, Lauren Thumm, Michelle Makiya, Irina Maric, Amy D Klion, Andrew A Lane

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Esther RheinbayBroad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0002-5566-6729
Meifang QiBroad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0002-8671-3110
Juliette M BouyssouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Andrew J OlerBioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-6310-0434
Lauren ThummClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD.
Michelle MakiyaLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD.ORCID 0000-0002-5673-3815
Irina MaricLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Amy D KlionLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD.ORCID 0000-0002-4986-5326
Andrew A LaneBroad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0001-7380-0226

Funding

Eosinophils and Eosinophil Activation in the Pathogenesis of Human DiseaseZIAAI001130 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KLION, AMY · 2010 to 2025
$22.5M
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)R37CA225191 · NCI · DANA-FARBER CANCER INST · PI LANE, ANDREW A · 2018 to 2024
$3.0M
Laboratory Assessment of Patients with Hypereosinophilic SyndromeZIACL080004 · CLC · CLINICAL CENTER · PI MARIC, IRINA · 2009 to 2025
$0k
NCI NIH HHS R37 CA225191
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hypereosinophilic SyndromeGenomicsHumans

Identifiers

PMID36652685
PMCPMC10250933

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.